Two hundred will receive HIVIG during pregnancy, and 200 participants will receive non-HIV specific immune globulin as a control group.
NABI, which owns all the rights to HIVIG, recently announced the establishment of a production facility to produce clinical trial quantities of HIVIG according to cGMP.
HIVIG is prepared from the plasma of HIV-antibody-positive donors who are healthy and have a strong immune response to the virus.
NABI's goal is to test the effectiveness of HIVIG in preventing the transmission of AIDS from HIV-positive mothers to unborn infants in clinical trials.
Immune globulin products such as HIVIG are antibody-laden substances derived from human plasma, used to immunize recipients against a viral or bacterial disease to which they have been exposed.